Beta Bionics Chief Product Officer Mike Mensinger sold 4,375 shares at $19.11 per share on September 2, 2026. His post-transaction holding was 180,040 shares, giving BBNX investors a specific view of the executive’s remaining stock position after the transaction.
Key Highlights
- The shares were sold at $19.11 each.
- Mike Mensinger owned 180,040 shares after the transaction.
- The sale took place on September 2, 2026.
$19.11 Share Sale Leaves 180,040 Shares
The transaction involved the company’s product chief and left Mensinger with 180,040 shares afterward. Mike Mensinger serves as Chief Product Officer at Beta Bionics (NASDAQ: BBNX). The shares were sold at $19.11 per share. The transaction took place on September 2, 2026. Mensinger’s ownership following the sale stood at 180,040 shares.
FAQs
Q: How many Beta Bionics shares did Mike Mensinger sell?
A: Mike Mensinger sold 4,375 Beta Bionics shares. The transaction price was $19.11 per share, and he held 180,040 shares after the sale.
Q: What does the BBNX executive share sale show?
A: The transaction identifies a sale by Beta Bionics Chief Product Officer Mike Mensinger. His reported ownership after the transaction was 180,040 shares.
Q: When did the Beta Bionics share sale occur?
A: The Beta Bionics share sale occurred on September 2, 2026. The shares were sold at $19.11 per share by Chief Product Officer Mike Mensinger.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.